Literature DB >> 9922823

Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature.

I Mathy1, M Gille, F Van Raemdonck, J Delbecq, A Depré.   

Abstract

We report the case of a 73-year-old man who developed an acute encephalopathy during IVIg therapy for AIDP. The signs and symptoms of the encephalopathy completely resolved after discontinuation of the treatment. We also reviewed the literature over the major neurological complications of IVIg therapy, including aseptic meningitis, cerebral infarction, and acute encephalopathy. About 30 cases of aseptic meningitis are reported. They are probably related to an immunoallergic reaction, caused by the entry of the exogenous IgG into the CSF compartment. CSF examinations usually show a neutrophilic or a mixed pleocytosis. Three cases of cerebral infarction and 2 patients with acute encephalopathy, following IVIg therapy, were also reported in the literature. Cerebral vasospasm, cerebral vasculitis, and/or serum hyperviscosity may be implicated in the pathogenesis of these neurological complications. There is a clinical similarity between these IVIg-related encephalopathy and the "reversible posterior leukoencephalopathy syndrome", described by Hinchey et al., 1996.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9922823

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  11 in total

1.  Posterior Reversible Encephalopathy Syndrome: Local Experience From Saudi Arabia.

Authors:  Hussein Algahtani; Abdulhadi Algahtani; Ahmad Aldarmahi; Mohammed Hmoud; Yousef Marzuk; Bader Shirah
Journal:  Neurohospitalist       Date:  2016-08-31

2.  Guillain Barré syndrome-related posterior reversible encephalopathy syndrome.

Authors:  Giulio Zuccoli; Raffaele Nardone; Abdel-Hamid Hoda
Journal:  Neuroradiology       Date:  2015-02-05       Impact factor: 2.804

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

4.  Posterior reversible encephalopathy syndrome (PRES) as a complication of Guillain-Barre' syndrome (GBS).

Authors:  Sumaira Nabi; Haris Majid Rajput; Mazhar Badshah; Shahzad Ahmed
Journal:  BMJ Case Rep       Date:  2016-08-03

Review 5.  Posterior leukoencephalopathy syndrome.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2001-01       Impact factor: 2.401

6.  Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Odile Spreux-Varoquaux; Aurelie Birenbaum; Marie Laure Chadenat; François Mignon; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 7.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

8.  Reversible posterior encephalopathy syndrome due to intravenous immunoglobulin in a child with Guillain-Barré syndrome.

Authors:  Faruk Incecik; M Ozlem Hergüner; Sakir Altunbasak; Dincer Yıldızdas
Journal:  J Pediatr Neurosci       Date:  2011-07

9.  Posterior reversible encephalopathy syndrome in a postpartum hemorrhagic woman without hypertension: A case report.

Authors:  Chon-Fu Lio; Ying-Hua Lee; Hung-Yen Chan; Chang-Ching Yu; Nan-Jing Peng; Hung-Pin Chan
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

10.  Guillain-Barre syndrome with posterior reversible encephalopathy syndrome.

Authors:  Basavaraj F Banakar; Guruprasad S Pujar; Amita Bhargava; Shubhkaran Khichar
Journal:  J Neurosci Rural Pract       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.